MCID: PRM227
MIFTS: 24

Primary Orthostatic Hypotension

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Primary Orthostatic Hypotension

MalaCards integrated aliases for Primary Orthostatic Hypotension:

Name: Primary Orthostatic Hypotension 53
Neurogenic Orthostatic Hypotension 53

Classifications:



Summaries for Primary Orthostatic Hypotension

NIH Rare Diseases : 53 Primary orthostatic hypotension is a rare type of orthostatic hypotension. It is not a disease per se, but a condition caused by several disorders that affect a specific part of the autonomic nervous system, such as multiple system atrophy, young-onset Parkinson�??s disease, pure autonomic failure, dopamine beta-hydroxylase deficiency, familial dysautonomia, and pure autonomic failure among others. The autonomic nervous system is the part of the nervous system that regulates certain involuntary body functions such as heart rate, blood pressure, sweating, and bowel and bladder control. Orthostatic hypotension is a form of low blood pressure that happens when standing-up from sitting or lying down. Common symptoms may include dizziness, lightheadedness, generalized weakness, leg buckling, nausea, blurry vision, fatigue, and headaches. Additional symptoms can include chest pain (angina), head and neck pain (often affecting neck and shoulders with a coat hanger distribution), decline in cognitive functioning such as difficulty concentrating, temporary loss of consciousness or �??blackout�?�. Some people with primary orthostatic hypotension may also have high blood pressure when lying down. The treatment depends upon several factors including the specific underlying cause including The treatment depends upon several factors including the specific underlying cause and may include physical counter-maneuvers like lying down, sitting down, squatting clenching buttocks, leg crossing, and support garment and medication.

MalaCards based summary : Primary Orthostatic Hypotension, also known as neurogenic orthostatic hypotension, is related to parkinson disease, late-onset and pure autonomic failure. An important gene associated with Primary Orthostatic Hypotension is ACHE (Acetylcholinesterase (Cartwright Blood Group)). The drugs Midodrine and Droxidopa have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and spinal cord.

Related Diseases for Primary Orthostatic Hypotension

Diseases related to Primary Orthostatic Hypotension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 12)
# Related Disease Score Top Affiliating Genes
1 parkinson disease, late-onset 10.6
2 pure autonomic failure 10.3
3 multiple system atrophy 1 10.2
4 neuropathy 10.2
5 diabetes mellitus, noninsulin-dependent 10.1
6 diabetes mellitus 10.1
7 atrial fibrillation 10.1
8 postural orthostatic tachycardia syndrome 10.1
9 diabetic autonomic neuropathy 10.1
10 autonomic neuropathy 10.1
11 achalasia 10.1
12 syncope 10.1

Graphical network of the top 20 diseases related to Primary Orthostatic Hypotension:



Diseases related to Primary Orthostatic Hypotension

Symptoms & Phenotypes for Primary Orthostatic Hypotension

Drugs & Therapeutics for Primary Orthostatic Hypotension

Drugs for Primary Orthostatic Hypotension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midodrine Approved Phase 4,Phase 2 133163-28-7, 42794-76-3 4195
2
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23651-95-8 443940
3
Norepinephrine Approved Phase 4,Phase 2 51-41-2 439260
4 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1
5 Adrenergic alpha-Agonists Phase 4,Phase 2
6 Cholinergic Agents Phase 4
7 Adrenergic Agents Phase 4,Phase 2,Early Phase 1
8 Sympathomimetics Phase 4,Phase 3,Phase 2
9 Pyridostigmine Bromide Phase 4 101-26-8
10 Autonomic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
11 Adrenergic Agonists Phase 4,Phase 2
12 Bromides Phase 4
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Early Phase 1
14 Anticonvulsants Phase 4
15 Cholinesterase Inhibitors Phase 4
16 Vasoconstrictor Agents Phase 4,Phase 2
17 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
19 Atomoxetine Hydrochloride Phase 4,Phase 2
20 Antihypertensive Agents Phase 4,Early Phase 1
21
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
22
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
23 Dopamine Agents Phase 3,Phase 2
24 Cardiotonic Agents Phase 3
25 Protective Agents Phase 3,Early Phase 1
26
Carbidopa Approved Phase 2 28860-95-9 34359 38101
27 Aromatic Amino Acid Decarboxylase Inhibitors Phase 2
28
Yohimbine Approved, Investigational, Vet_approved Early Phase 1 146-48-5 8969
29
Melatonin Approved, Nutraceutical, Vet_approved Early Phase 1 73-31-4 896
30 Antioxidants Early Phase 1
31 Mydriatics Early Phase 1
32 Adrenergic Antagonists Early Phase 1
33 Adrenergic alpha-Antagonists Early Phase 1
34 Yohimbe Early Phase 1
35 Central Nervous System Depressants Early Phase 1

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study Completed NCT02308124 Phase 4 Midodrine;Pyridostigmine Bromide;Midodrine + pyridostigmine
2 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4 Midodrine Hydrochloride
3 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
4 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
5 Brain Perfusion & Oxygenation in Parkinson's Disease With NOH Recruiting NCT03229174 Phase 4 Droxidopa;Placebo
6 Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH Recruiting NCT03350659 Phase 4 Midodrine;Atomoxetine
7 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
8 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4 midodrine hydrochloride (ProAmatine®)
9 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3 Droxidopa;Placebo
10 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) Completed NCT01132326 Phase 3 Droxidopa
11 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
12 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
13 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Completed NCT01176240 Phase 3 Droxidopa
14 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure Recruiting NCT03750552 Phase 3 TD-9855;Placebo
15 A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy Terminated NCT01927055 Phase 3 Droxidopa;Placebo
16 Fipamezole in Neurogenic Orthostatic Hypotension Unknown status NCT00758849 Phase 2 Placebo;Fipamezole
17 Abdominal Binder to Treat Orthostatic Hypotension (OH) in Parkinson's Disease (PD) Completed NCT01971008 Phase 2
18 Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension Completed NCT00004268 Phase 2 midodrine
19 Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa Completed NCT00983814 Phase 2 Droxidopa+Carbidopa;Placebo
20 Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH) Recruiting NCT03567447 Phase 2 Droxidopa
21 Norepinephrine Transporter Blockade, Autonomic Failure (NETAF) Recruiting NCT02784535 Phase 2 Atomoxetine;Placebo
22 Norepinephrine Transporter Blockade, Autonomic Failure Recruiting NCT02796209 Phase 2 Atomexetine;Placebo
23 Carbidopa for the Treatment of Excessive Blood Pressure Variability Recruiting NCT02553265 Phase 2 Carbidopa Low Dose;Carbidopa High Dose
24 TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Active, not recruiting NCT02705755 Phase 2 TD-9855;Placebo
25 Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome Terminated NCT00977171 Phase 2 Droxidopa
26 Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa Completed NCT01149629 Phase 1 Droxidopa;Droxidopa;Droxidopa
27 Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension Completed NCT01316666
28 Abdominal Compression in Orthostatic Hypotension Completed NCT01223391 Not Applicable
29 Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension Recruiting NCT02963181 Early Phase 1 Yohimbine;Melatonin
30 Natural History Study of Synucleinopathies Recruiting NCT01799915
31 Cardiovascular Effects of Exercise in Patients With Parkinson's Disease Recruiting NCT03343574 Not Applicable
32 Multiple System Atrophy Multidisciplinary Clinic Recruiting NCT03811808
33 Breathing Device for Orthostatic Hypotension (OH) Active, not recruiting NCT00962884 Not Applicable

Search NIH Clinical Center for Primary Orthostatic Hypotension

Genetic Tests for Primary Orthostatic Hypotension

Anatomical Context for Primary Orthostatic Hypotension

MalaCards organs/tissues related to Primary Orthostatic Hypotension:

41
Heart, Brain, Spinal Cord, Testes

Publications for Primary Orthostatic Hypotension

Articles related to Primary Orthostatic Hypotension:

(show top 50) (show all 121)
# Title Authors Year
1
Impaired cortical autonomic responses during sympathetic activation in Neurogenic Orthostatic Hypotension characterized by post-ganglionic autonomic dysfunction. ( 29901433 )
2018
2
Evaluating the effectiveness of atomoxetine for the treatment of primary orthostatic hypotension in adults. ( 29569329 )
2018
3
Correction to: Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. ( 29185076 )
2018
4
A patient with autonomic imbalance: Treating symptomatic neurogenic orthostatic hypotension. ( 29757831 )
2018
5
Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. ( 29972032 )
2018
6
Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers. ( 30144800 )
2018
7
Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension. ( 30229336 )
2018
8
Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. ( 30232253 )
2018
9
Impaired cortical autonomic responses during sympathetic activation in neurogenic orthostatic hypotension characterized by postganglionic autonomic dysfunction. ( 30332348 )
2018
10
Validation of the new diagnostic tests for neurogenic orthostatic hypotension. ( 30341958 )
2018
11
A validated test for neurogenic orthostatic hypotension at the bedside. ( 30341962 )
2018
12
Cerebellar impairment during an orthostatic challenge in patients with neurogenic orthostatic hypotension. ( 30527385 )
2018
13
Use of droxidopa for the long-term treatment of neurogenic orthostatic hypotension. ( 30535274 )
2018
14
Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension. ( 28623420 )
2017
15
Comparison of Heart Rate Variability Parameters to the Autonomic Reflex Screen in Postural Orthostatic Tachycardia Syndrome and Neurogenic Orthostatic Hypotension. ( 29210841 )
2017
16
The Treatment of Primary Orthostatic Hypotension. ( 28092986 )
2017
17
Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease. ( 28699048 )
2017
18
Erratum to: Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease. ( 28889358 )
2017
19
Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy. ( 28631222 )
2017
20
Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease. ( 28674866 )
2017
21
Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease. ( 28674867 )
2017
22
Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus. ( 28674868 )
2017
23
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension. ( 28699047 )
2017
24
Erratum to: Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension. ( 28889359 )
2017
25
Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease. ( 28631223 )
2017
26
Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease. ( 28631224 )
2017
27
Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension. ( 28634637 )
2017
28
The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. ( 28050656 )
2017
29
Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson's disease. ( 28125950 )
2017
30
Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. ( 28159196 )
2017
31
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. ( 28494751 )
2017
32
Neurogenic orthostatic hypotension: the very basics. ( 28620715 )
2017
33
Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn? ( 28623419 )
2017
34
Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension. ( 28702747 )
2017
35
Epidemiology, Diagnosis, and Management of Neurogenic Orthostatic Hypotension. ( 28713844 )
2017
36
Corrigendum to: Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson's disease. ( 28885073 )
2017
37
Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol. ( 28902695 )
2017
38
Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. ( 29058089 )
2017
39
Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension. ( 27614923 )
2016
40
Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303). ( 27636856 )
2016
41
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension. ( 27538531 )
2016
42
Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension. ( 27622314 )
2016
43
Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data. ( 26710315 )
2016
44
Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension. ( 26951135 )
2016
45
Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. ( 27332626 )
2016
46
Neurogenic orthostatic hypotension with critical illness neuropathy treated with droxidopa. ( 27423298 )
2016
47
Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. ( 27478953 )
2016
48
Droxidopa in neurogenic orthostatic hypotension. ( 26092297 )
2015
49
Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. ( 25350981 )
2015
50
Prospects for droxidopa in neurogenic orthostatic hypotension. ( 25350983 )
2015

Variations for Primary Orthostatic Hypotension

Expression for Primary Orthostatic Hypotension

Search GEO for disease gene expression data for Primary Orthostatic Hypotension.

Pathways for Primary Orthostatic Hypotension

GO Terms for Primary Orthostatic Hypotension

Sources for Primary Orthostatic Hypotension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....